



Investing in our future

The Global Fund

To Fight AIDS, Tuberculosis and Malaria

tel
fax
email

+41 (0)22 791 1700
+41 (0)22 791 1701
info@theglobalfund.org

Chemin de Blandonnet 8 • 1214 Vernier • Geneva, Switzerland

www.theglobalfund.org

1 November 2007

Mr. Milo Stanojevich
Country Director
CARE PERU
Av. Gral. Santa Cruz N° 659
Jesús Maria – Lima
Peru

**Subject: Program Grant Agreement Number PER-506-G03-H
Implementation Letter Number 2**

Dear Mr Stanojevich,

We refer to the Program Grant Agreement between The Global Fund to Fight AIDS, Tuberculosis and Malaria (the "Global Fund") and CARE Peru (the "Principal Recipient") for a HIV/AIDS program entitled "Closing Gaps to Achieve Millennium Development Goals for HIV/AIDS in Peru", effective 26 June 2006 and amended by letter dated 22 September 2006 (as amended from time to time, the "Grant Agreement"). Capitalized terms used but not defined in this letter have the meaning given to them in the Grant Agreement.

We acknowledge that the Country Coordinating Mechanism (CCM) has requested a one-month extension to the Program as a result of the earthquake that occurred in Peru on 15 August 2007, which significantly delayed program implementation. The Global Fund has considered this request and has agreed to grant the extension, which will amend the Phase 1 Ending Date to 30 September 2008 and the Phase 2 Ending Date to 30 September 2011. This implementation letter serves to put that extension into place.

We are also taking the opportunity to update the name of the Local Fund Agent in Block 12 of the face sheet of the Grant Agreement and the Global Fund Additional Representative in Block 14 of the face sheet of the Grant Agreement.

By signing this implementation letter, the Global Fund and the Principal Recipient agree to amend blocks 4A, 6, 7, 12 and 14 of the face sheet of the Grant Agreement as follows:

Block 4A: Modification Number: 2 (Implementation Letter 2 dated 1 November 2007)

Block 6: Phase 1 Ending Date: 30 September 2008

Block 7: Phase 2 Ending Date: 30 September 2011

Block 12: Local Fund Agent ("LFA"):
PricewaterhouseCoopers S.Civil.R.L
Av. Canaval y Moreyra 380, Piso 13, San Isidro, Lima - Peru
Tel: +51 1 211 6500
Fax: +51 1 211 6565 Attention: Mr. Sergio Korembliit
E-mail: sergio.korembliit@pe.pwc.com

Block 14: Name/Address for Notices to Global Fund:
Lelio Marmora
Team Leader a.i.
Latin America and the Caribbean
Chemin de Blandonnet 8
1214 Vernier—Geneva, Switzerland
Tel : +41 22 791 1700
Fax: +41 22 791 1701

The Grant Agreement is further amended by adding to Annex A of the Grant Agreement the document entitled "Attachment 1&2a to Annex A: Indicators, Targets and Periods Covered" attached to this letter to reflect the one-month increase in the length of Period 5 of the Program.

Except as modified herein, the Grant Agreement remains in full force and effect.

This amendment shall come into force on the date of signature of this letter by both parties. Please confirm your agreement with the foregoing by signing both enclosed copies of this letter and returning one to us, retaining one copy for your records.

We thank you and your partners for undertaking this important effort in the global fight against HIV/AIDS. We look forward to the successful implementation of the Program.

Yours sincerely,

Helen Evans
Deputy Executive Director

Agreed and Signed:

For: CARE PERU

By: _____
Authorized Representative: Mr. Milo Stanojevich, Country Director

Date: November 19, 2007

cc: Dr. Carlos Vallejos Sologuren, CCM Chair
Mr. Oscar la Torre, LFA

Attachment: amended face sheet of the Grant Agreement
Attachment 1&2a to Annex A of the Grant Agreement



Investing in our future

The Global Fund

To Fight AIDS, Tuberculosis and Malaria

PROGRAM GRANT AGREEMENT

1. Country: Peru		
2. Principal Recipient Name and address: CARE Perú, Av. Gral. Santa Cruz N° 659, Jesús María – Lima, Peru		
3. Program Title: Closing Gaps to Achieve Millennium Development Goals for HIV/AIDS in Peru		
4. Grant Number: PER-506-G03-H		4A. Modification Number: 2 (Implementation Letter 2 dated 1 November 2007)
5. Phase 1 Starting Date: 1 September 2006	6. Phase 1 Ending Date: 30 September 2008	7. Phase 2 Ending Date: 30 September 2011
7A. Condition Precedent Terminal Date: 30 June 2006	7B. Condition Precedent Terminal Date: 15 October 2006	7C. Condition Precedent Terminal Date: 30 August 2006
7D. Condition Precedent Terminal Date: 30 June 2006	7E. Condition Precedent Terminal Date: N/A	7F. Condition Precedent Terminal Date: N/A
8. Grant Funds: US\$ 8,061,442 (Eight million, and sixty one thousand, four hundred and forty two United States Dollars)		
9. Program Coverage: <input checked="" type="checkbox"/> HIV/AIDS <input type="checkbox"/> Tuberculosis <input type="checkbox"/> Malaria <input type="checkbox"/> Health Systems Strengthening		
10. Information for Principal Recipient Bank Account into Which Grant Funds Will Be Disbursed:		
11. The fiscal year of the Principal Recipient is from 1 June to 31 May.		
12. Local Fund Agent ("LFA") PricewaterhouseCoopers S.Civil.R.L Av. Canaval y Moreyra 380, Piso 13, San Isidro, Lima - Peru Tel: +51 1 211 6500 Fax: +51 1 211 6565 Attention: Mr. Sergio Korembli E-mail: sergio.korembli@pe.pwc.com		
13. Name/Address for Notices to Principal Recipient Dr. Virginia Baffigo de Pinillos National Coordinator CARE Perú Av. Gral. Santa Cruz N° 659 Jesús María – Lima, Peru Tel: +51 1 431 7430 Fax: +51 1 433 0492 Email: vbaffigo@care.org.pe		14. Name/Address for Notices to Global Fund: Lelio Marmora Team Leader a.i. Latin America and the Caribbean Chemin de Blandonnet 8 1214 Vernier-Geneva, Switzerland Tel: +44 22 791 1700 Fax: +41 22 791 1701
This Agreement consists of the two pages of this face sheet and the following:		
Standard Terms and Conditions		Annex A – Program Implementation Description

Attachment 1.6 to Annex A: Indicators, Targets, and Periods Covered

Country:	PERU
State:	IN/ADIS
Grant number:	PER-500-0041
Principal Investigator:	CARE PERU

Indicator	Period 1	Period 2	Period 3	Period 4
1. Prevalence of HIV	1 December 2005 - 28 February 2007	1 March - 31 May 2007	1 June - 31 August 2007	1 September - 31 November 2007
2. New HIV infections	1 December 2005 - 28 February 2007	1 March - 31 May 2007	1 June - 31 August 2007	1 September - 31 November 2007
3. Percentage of people who are on ART	1 September - 31 December 2005	1 January - 31 March 2006	1 April - 30 June 2006	1 July - 30 September 2006
4. Percentage of people who are on ART and taking their medication	1 September - 31 December 2005	1 January - 31 March 2006	1 April - 30 June 2006	1 July - 30 September 2006

Annual Report Due Year 1:	31-Mar-07
Annual Report Due Year 2:	31-Mar-08
Annual Report Due Year 3:	31-Mar-09

Indicator	Objective	Measurement	Target	Period
1	Prevalence of HIV	Prevalence of HIV	40% decrease of the baseline	1-2
2	New HIV infections	Prevalence of HIV	40% decrease of the baseline	1-2
3	Percentage of people who are on ART	Prevalence of HIV	40% decrease of the baseline	1-2
4	Percentage of people who are on ART and taking their medication	Prevalence of HIV	40% decrease of the baseline	1-2

Indicator	Objective	Measurement	Target	Period
1 Impact	Incidence rate in men who have sex with men (MSM)	MSM information system - OGE	0.50%	2002
2 Impact (Round 2 and Round 3)	Percentage of program women infected with HIV	MSM information system - OGE	0.20%	2002
3 Impact	Percentage of adults and children who are on ART	MSM information system - OGE	70%	2005
4 Impact	Percentage of 574 in young people and adolescents (15-24 years of age)	MSM information system - OGE	70%	2005
5 Outcome (Round 2 and Round 3)	Number and percentage of people who used condoms in their last sexual encounter	Programme monitoring system	63%	2003
6 Outcome (Round 2 and Round 3)	Number and percentage of young people (15-24 years old) who used condoms in their last sexual encounter	Programme monitoring system	53%	2003
7 Outcome (Round 2 and Round 3)	Number and percentage of men who have sex with men (MSM) who used condoms in their last sexual encounter	MSM information system - OGE	80%	2003
8 Outcome (Round 2 and Round 3)	Number and percentage of sex workers who used condoms in their last sexual encounter	MSM information system - OGE	84%	2003
9 Outcome (Round 2 and Round 3)	Number and percentage of men who have sex with men (MSM) who used condoms in their last sexual encounter	MSM information system - OGE	70%	2004
10 Outcome (Round 2 and Round 3)	Percentage of PLWHA who started ART treatment during baseline study	MSM information system - OGE	40%	2005
11 Outcome	Percentage of the population of the regions intervenes who are on ART	MSM information system - OGE	50%	2005
12 Outcome	Percentage of the population of the regions intervenes who are on ART and taking their medication	MSM information system - OGE	30%	2005
13 Outcome	Number of PLWHA who are on ART and taking their medication	MSM information system - OGE	30%	2005
14 Outcome	Number of PLWHA who are on ART and taking their medication	MSM information system - OGE	30%	2005
15 Outcome	Number of PLWHA who are on ART and taking their medication	MSM information system - OGE	30%	2005

Indicator	Objective	Measurement	Target	Period
1	Prevalence of HIV	Prevalence of HIV	40% decrease of the baseline	1-2
2	New HIV infections	Prevalence of HIV	40% decrease of the baseline	1-2
3	Percentage of people who are on ART	Prevalence of HIV	40% decrease of the baseline	1-2
4	Percentage of people who are on ART and taking their medication	Prevalence of HIV	40% decrease of the baseline	1-2

